Coronary Vascular Pharmacology

  • Marco N. Diaz
  • Richard A. Cohen
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)


This chapter reviews a basic understanding of coronary artery physiology and pharmacology. Mechanisms of physiological control of coronary blood flow are discussed first. This serves as a basis for a discussion of the major classes of drugs used clinically which affect coronary blood flow including nitrates, angiotension converting enzyme inhibitors, calcium channel blockers, and alpha- and beta-adrenergic antagonists. The mechanism of action of each drug class, the evidence for its effects on coronary blood flow, and its clinical use in myocardial infarction, and acute and chronic myocardial ischemia are reviewed.


Acute Myocardial Infarction Calcium Channel Blocker Unstable Angina Beta Blocker Coronary Blood Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schlant RC, Sonnenblick EH. Normal physiology of the cardiovascular system. In Schlant RC, Alexander RW (eds). The Heart. New York: McGraw-Hill, 1994:113.Google Scholar
  2. 2.
    Braunwald E, Sobel BE. Coronary blood flow and myocardial ischemia. In Braunwald E. (ed). Heart Disease. Philadelphia: WB Saundcrs, 1992:1161.Google Scholar
  3. 3.
    Fung HL, Chung SJ, Bauer JA, Chong S, Kowaluk EA. Biochemical mechanism of organic nitrate action. Am J Cardiol 70:4B, 1992.PubMedCrossRefGoogle Scholar
  4. 4.
    Rutherford JD, Braunwald E. Chronic Ischemie Heart Disease. In Braunwald E (ed). Heart Disease. Philadelphia: WB Saunders, 1992:1292.Google Scholar
  5. 5.
    Abrams J. Mechanisms of action of the organic nitrates in the treatment of myocardial ischemia. Am J Cardiol 70:30B, 1992.PubMedCrossRefGoogle Scholar
  6. 6.
    Brown BG, Bolson E, Petersen RB, Pierce CD, Dodge HT. The mechanisms of nitroglycerin action: Stenosis vasodilatation as a major component of the drug response. Circulation 61:1089, 1981.Google Scholar
  7. 7.
    Cowan C, Duran PVM, Corsini G. The effects of nitroglycerin on myocardial blood flow in man. Measured by coincidence counting and bolus injections of 84rubidium. Am J Cardiol 24:154, 1969.PubMedCrossRefGoogle Scholar
  8. 8.
    Parker JO, West RO, Di Giorgi S. The effect of nitroglycerin on coronary bood flow and the hemodynamic response to exercise in coronary artery disease. Am J Cardiol 27:59, 1971.PubMedCrossRefGoogle Scholar
  9. 9.
    Ganz W, Marcus HS. Failure of intracoronary nitroglycerin to alleviate pacing-induced angina. Circulation 46:880, 1972.PubMedGoogle Scholar
  10. 10.
    Fam WM, McGregor M. Effect of coronary vasodilator drugs on retrograde flow in areas of chronic myocardial ischemia. Circ Res 15:355, 1964.PubMedGoogle Scholar
  11. 11.
    Cohen MV, Downey JM, Sonnenblick EH. The effects of nitroglycerin on coronary collaterals and myocardial contractility. J Clin Invest 52:2836, 1973.PubMedGoogle Scholar
  12. 12.
    Cohn PF, Maddox D, Holman BL, Markis JE, Adams DF, See JR. Effect of sublingually administered nitroglycerin on regional myocardial blood flow in patients with coronary artery disease. Am J Cardiol 39:672, 1977.PubMedCrossRefGoogle Scholar
  13. 13.
    Hill JA, Feldman RL, Pepine CJ, Conti CR. Randomized double-blind comparison of nifedipine and isosorbidc dinitrate in patients with coronary arterial spasm. Am J Cardiol 49:431, 1982.PubMedCrossRefGoogle Scholar
  14. 14.
    Ginsburg R, Lamb I, Schroeder JS, Hu M, Harrison DC. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary arterial spasm. Am Heart J 103:44, 1982.PubMedCrossRefGoogle Scholar
  15. 15.
    Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconsuiction induced by acecylcholine atherosclerotic arteries. N Engl J Med 315:1046, 1986.PubMedCrossRefGoogle Scholar
  16. 16.
    Golino P, Piccione F, Willerson JT. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 324:641, 1986.CrossRefGoogle Scholar
  17. 17.
    Flaherty JT, Come PC, Baird MG, Kelly DT. Intravenous nitroglycerin in acute myocardial infarction. Circulation 51:132, 1975.PubMedGoogle Scholar
  18. 18.
    Flaherty JT. Role of nitrates in acute myocardial infarction. Am J Cardiol 70:73B, 1992.PubMedCrossRefGoogle Scholar
  19. 19.
    Jugdutt BI. Role of nitrates after acute myocardial infarction. Am J Cardiol 70:82B, 1992.PubMedCrossRefGoogle Scholar
  20. 20.
    Flaherty JT, Becker LC, Bulkley BH, Weiss JL, Gerstenblith G, Kallman CH, Silverman KJ, Wei JY, Pitt B, Weisbeldt ML. A randomized prospective trial of intravenous nitroglycerin in patients with acute myotardial infarction. Circulation 68:576, 1983.PubMedGoogle Scholar
  21. 21.
    Jugdutt BI, Warnica JW. Intravenous nitroglycerin cherapy to limit myocardial infant size, expansion and complications. Effect of timing, dosage and infarcr location. Circulation 78:906, 1988.PubMedGoogle Scholar
  22. 22.
    Yusuf S, Collins R, MacMahon S, Peto S. Effect of intravenous nitrates on mortality in acute myocardial infarction: An overview of the randomized trials. Lancet 1:1088, 1988.PubMedCrossRefGoogle Scholar
  23. 23.
    Gruppo Italiano per lo Studio delia Soprawivenza nell’infarto Miocardico. GlSSl-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115, 1994.Google Scholar
  24. 24.
    lSlS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345:669, 1995.CrossRefGoogle Scholar
  25. 25.
    Brown BG, Lee AB, Bolson EL, Dodge HT. Reflex constriction of significant coronary stenosis as a direct mechanism contributing to ischemic left ventricular dysfunction during isometric exercise. Circulation 70:18, 1984.PubMedGoogle Scholar
  26. 26.
    Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol 70:18B, 1992.PubMedCrossRefGoogle Scholar
  27. 27.
    Curfman GD, Heinsimes JA, Lozner EC, Fung HL. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: A prospective randomized trial. Circulation 67:286, 1983.Google Scholar
  28. 28.
    Horowitz JD. Role of nitrates in unstable angina pectoris. Am J Cardiol 70:64B, 1992.PubMedCrossRefGoogle Scholar
  29. 29.
    Horowiicz JD, Henry CA, Syrjanen ML. Combinned use of nitroglycerine and N-acetylcysteine in the management of unstable angina pectoris. Circulation 77:787, 1988.Google Scholar
  30. 30.
    Murrell W. Nitro-glycerine as a remedy for angina pectoris. Lancet 1:80, 1879.CrossRefGoogle Scholar
  31. 31.
    Detry JMR, Bruce RA. Effects of nitroglycerin on “maximal” oxygen intake and exercise electrocardiogram in coronary artery disease. Circulation 43:629, 1971.Google Scholar
  32. 32.
    Thadani U. Role of nitrates in angina pectoris. Am J Cardiol 70:43B, 1992.PubMedCrossRefGoogle Scholar
  33. 33.
    Abrams J. New concepts on using nitrates in angina pectoris. Contemp Intern Med 1991:92.Google Scholar
  34. 34.
    Banowitz NC, Bourne HR. Antihypertensive Agents. In Katzung, BG (ed). Basic and Clinical Pharmacology. Appleton and Lang, 1987:105.Google Scholar
  35. 35.
    Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 319:1517, 1988.PubMedCrossRefGoogle Scholar
  36. 36.
    Lonn EM, Yusuf S, Jha P, Doris Cl, Sabine MJ, Dzavik V, Hutchison K, Riley WA, Tucker J, Pogue J, Taylor W. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90:2056, 1994.PubMedGoogle Scholar
  37. 37.
    Kelly RA, Smith TW. Pharmacologic treatment of heart failure. In Hardman J, Limbird L, Molinoff P, Ruddon RW, Gilman AG, Goodman LS (eds). The Pharmacologie Basis of Therapeutics, New York: McGraw Hill, 1996.Google Scholar
  38. 38.
    Davies MK. Effecrs of ACE inhibitors on coronary haemodynamics and angina pectoris. Br Heart J 72:S52, 1994.PubMedCrossRefGoogle Scholar
  39. 39.
    Van Gilst WH, Van Wigorgaarden J, Scholters E, de Grueff PA, deLarger CDJ, Wesseling H. Captoprilinduced increase in coronary flow: An SH-dependent effect on arachidonic acid metabolism? J Cardiovasc Pharmacol 9:S31, 1987.PubMedGoogle Scholar
  40. 40.
    Karsch KR, Voelker W, Mauser M. Myocardial and coronary effects of captopril during pacing-induced ischaemia in patients with coronary artery disease. Eur Heart J 11:157, 1990.PubMedGoogle Scholar
  41. 41.
    Ikram H, Low CJ, Shirlaw T, Webb CM, Richards AM, Crozier IG. Antianginal, hemodynamic and coronary vascular effects of catopril in stable angina pectoris. Am J Cardiol 66:164, 1990.PubMedCrossRefGoogle Scholar
  42. 42.
    AlRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821, 1993.Google Scholar
  43. 43.
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685, 1992.CrossRefGoogle Scholar
  44. 44.
    Pfeffer MA, Braunwald E, Moyc LA, Basta L, Brown EJ Jr., Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH. Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction; Results of the survival and ventricular enlargement trial. N Engl J Med 327:669, 1992.PubMedCrossRefGoogle Scholar
  45. 45.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293, 1991.CrossRefGoogle Scholar
  46. 46.
    Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekens CH. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 6:556, 1985.PubMedGoogle Scholar
  47. 47.
    Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 95:995, 1995.PubMedCrossRefGoogle Scholar
  48. 48.
    Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction; Results of the cooperative New Scandinavian Enalapri Survival Study II (Consensus II). N Engl J Med 327:678, 1992.PubMedCrossRefGoogle Scholar
  49. 49.
    Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319:80, 1988.PubMedCrossRefGoogle Scholar
  50. 50.
    Greenwald L, Becker RC Expanding the paradigm of the renin-angiotensin system and angiotensinconverting enzyme inhibitors. Am Heart J 128:997, 1994.PubMedCrossRefGoogle Scholar
  51. 51.
    Chobanian AV. The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis. Clin Cardiol 13:VII43, 1990.PubMedGoogle Scholar
  52. 52.
    Rolland PH, Charpiot P, Friggi A, Piquet P, Barlatier A, Scalbert E, Bodard H, Tranier P, Mercier C, Luccioni R, Garcon D. Effects of angiotensin-converting enzyme inhibition with perindolol on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol 71:22e, 1993.PubMedCrossRefGoogle Scholar
  53. 53.
    Gibbs JS, Crean PA, Mockus L, Wright C, Sutton GC, Fox KM. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. Br Heart J 62:112, 1989.PubMedCrossRefGoogle Scholar
  54. 54.
    Thurmann P, Odenthal HJ, Rietbrock N. Converting enzyme inhibition in coronary artery disease: A randomised, placebo-controlled trial with benazepril. J Cardiovasc Pharmacol 17:718, 1991.PubMedCrossRefGoogle Scholar
  55. 55.
    Klein WW, Khurmi NS, Eber B, Dusleag J. Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina. J Am Coll Cardiol 16:948, 1990.PubMedGoogle Scholar
  56. 56.
    Ikram H, Low CJ, Shirlaw T. Angiotensin converting enzyme inhibition in chronic stable angina: Effects on myocardial ischaemia and comparison with nifedipine. Br Heart J 71:30, 1994.PubMedCrossRefGoogle Scholar
  57. 57.
    Stompe KO, Overlack A. A new trial of the efficacy, tolerability, and safety of angiotensin converting enzyme inhibition in mild systemic hypertension with concomitant disease and therapies, Am J Cardiol 71:32E, 1993.CrossRefGoogle Scholar
  58. 58.
    Akhras F, Jackson G, The role of captopril as single therapy in hypertension and angina pectoris. Int J Cardiol 33:259, 1991.PubMedCrossRefGoogle Scholar
  59. 59.
    Wood AJJ. Calcium antagonists. Circulation 80:IV84, 1989.Google Scholar
  60. 60.
    Weiner DW, Klein MD. Calcium Antagonist for the Treatment of Angina Pectoris. In Weiner DW, Frishman WH (eds). Therapy of Angina Pectoris. New York: Marcel Dekker, 1986:145.Google Scholar
  61. 61.
    Frohlich ED. Calcium antagonists as cardioprotective agents. Am J Cardiol 70:71, 1992.CrossRefGoogle Scholar
  62. 62.
    Frishman WH. Current status of calcium channel blockers. Curr Probl Cardiol 19:637, 1994.PubMedCrossRefGoogle Scholar
  63. 63.
    Epstein M. Calcium antagonists should continue to be used for first-line trearmenr of hypertension. Arch Intern Med 155:2150, 1995.PubMedCrossRefGoogle Scholar
  64. 64.
    Vatner SF, Hintze TH. Effects of a calcium-channel antagonist on large and small coronary arteries in conscious dogs. Circulation 66:579, 1982.PubMedGoogle Scholar
  65. 65.
    Bache RJ. Effects of calcium entry blockade on myocardial blood flow. Circulation 80:IV40, 1989.PubMedGoogle Scholar
  66. 66.
    Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: Reversibility by nitroglycerin. Circulation 73:865, 1986.PubMedGoogle Scholar
  67. 67.
    Nonogi H, Hess OM, Ritter M, Bortone A, Corin WJ, Grimm J, Krayenbuehl HP. Prevention of coronary vasoconstriction by diltiazem during dynamic exercise in patients with coronary artery disease. J Am Coll Cardiol 12:892, 1988.PubMedGoogle Scholar
  68. 68.
    Kloner RA, Reimer K, Jennings R. Distribution of coronary collateral flow in acute myocardial ischemic injury. Cardiovasc Res 10:81, 1976.PubMedGoogle Scholar
  69. 69.
    Nayler WG, Ferrari R, Williams A. Protective effect of pretreatment with verapami), nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium. Am J Cardiol 46:242, 1980.PubMedCrossRefGoogle Scholar
  70. 70.
    The Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 9:354, 1988.Google Scholar
  71. 71.
    SPRINT Study Group. The Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) II. Design, methods and results. Eur Heart J 9:350A, 1988.Google Scholar
  72. 72.
    Wilcox RG, Hampton JR, Banks DC. Trial of nifedipine in acute myocardial infarction: The TRENT Study. Br Med J 293:1204, 1986.Google Scholar
  73. 73.
    Held PH, Yusuf S. Effects of-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 14(Suppl F):18, 1993.PubMedGoogle Scholar
  74. 74.
    Multicenter Diltiazem Postinfarction Trial Research Group. The effect of dilriazem on mortality and reinfarction after myocardial infarction. N F.ngl J Med 319:385, 1988.Google Scholar
  75. 75.
    Gibson RS, Boden WE, Theroux P. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. N Engl J Med 315:423, 1986.PubMedCrossRefGoogle Scholar
  76. 76.
    Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 5:516, 1984.Google Scholar
  77. 77.
    The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 66:779, 1990.CrossRefGoogle Scholar
  78. 78.
    Theroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 5:717, 1995.CrossRefGoogle Scholar
  79. 79.
    Gerstenblith G, Ouyang P, Achuff SC, Bulkley BH, Becker LC, Mellits ED, Baughman KL, Weiss JL, Flaherty JT, Kallman CH, Llewellyn M, Weisfeldt ML. Nifedipine in unstable angina. N Engl J Med 306:885, 1982.PubMedCrossRefGoogle Scholar
  80. 80.
    Holland Interuniversity Nifedipine/Metoprolol Trial Research Group. Early treatment of unstable angina in the coronary care unit: A randomized, double-blind, placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Br Heart J 56:400, 1986.CrossRefGoogle Scholar
  81. 81.
    Bala Subnamanian V, Khurmi NS, Bowles MJ, O’Hara M, Ratery FB. Objective evaluation of three dose levels of diltiazem in patients with chronic stable angina. J Am Coll Cardiol 1:1144, 1983.Google Scholar
  82. 82.
    Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 153:586, 1948.PubMedGoogle Scholar
  83. 83.
    Hoffman BB. Catecholamines, sympathomimetic druys and adrenergic receptor antagonist. In Hardman E, Lindbery CH, Mclinitt K, Ruddon RW (eds). The Pharmacological Basis of Therpeutics. New York: McGraw Hill, 1995.Google Scholar
  84. 84.
    Frishman WH. Multifactorial actions of beraadrenergic blocking drugs in ischmic heart disease: Current concepts. Circulation 67:1–11, 1983.Google Scholar
  85. 85.
    Becker LC, Fortuin NJ, Pitt B. Effect of ischemia and antianginal drugs on the distribution of radioactive microspheres in the canine left ventricle. Ore Res 28:263, 1971.Google Scholar
  86. 86.
    Vatner SF, Baig H, Manders WT, Ochs H. Effects of propranolol on regional myocardial function, electrograms, and blood flow in conscious dogs with myocardial ischemia. J Clin Invest 60:353, 1977.PubMedGoogle Scholar
  87. 87.
    Graham RM. Selective alpha-adrenergic antagonists: Therapeutically relevant antihypertensive agents. Am J Cardiol 16A, 1984.Google Scholar
  88. 88.
    The International Collaborative Study Group. Reduction of infarct size with the early use of timolol in aorta myocardial infarction. N Engl J Med 310:9, 1984.CrossRefGoogle Scholar
  89. 89.
    Singh BN. Advantages of beta-blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction. Am J Cardiol 66:9C, 1990.PubMedCrossRefGoogle Scholar
  90. 90.
    ISIS-1 Collaborative Group. Randomised trial of intravenous arenolol among 16,027 cases of suspected acute myocardial infarction. Lancet 2:57, 1986.Google Scholar
  91. 91.
    The TIM1 Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction. N Engl J Med 6320:618, 1989.Google Scholar
  92. 92.
    The Norwegian Mulucenter Study Group. Timololinduced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801, 1981.CrossRefGoogle Scholar
  93. 93.
    Beta Blocker Heart Attack Trial Research Group. A randomized trial oif propranolol in patients with acute myocardial infarction: 1. Mortality results. JAMA 247:1701, 1982.Google Scholar
  94. 94.
    Gottlieb SO, Weisfeldt ML, Ouyang P, Achuff SC, Baughman KL, Traill TA, Brinker JA, Shapiro EP, Chandra NC, Mellits ED, Townsend SN, Gerstenblith G. Effect of the addition of propranolol to therapy with nitedipine for unstable angina pectoris: A randomized, double-blind, placebo-controlled trial. Circulation 73:331, 1986.PubMedGoogle Scholar
  95. 95.
    Frishman WH. Beta adrenergic blockade tor treatment of angina pectoris. In Weiner DA, Frishman WH (ed). Therapy of Angina Pectoris. Marcel Dekker, New York: 1986:83.Google Scholar
  96. 96.
    Fox KM, Mulcahy D, Purcell H. Unstable and stable angina. Eur Heart J 14:15, 1993.PubMedGoogle Scholar
  97. 97.
    Cohen RA, Shepherd JT, Vanhoutte PM. Effects of the adrenergic transmitter on epicardial coronary arteries. Fed Proc 43:2862, 1984.PubMedGoogle Scholar
  98. 98.
    Tzivoni D, Keren A, Benhorin J. Prazosin therapy tor refractory variant angina. Am Heart J 105:262, 1983.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Marco N. Diaz
  • Richard A. Cohen

There are no affiliations available

Personalised recommendations